294 related articles for article (PubMed ID: 25018107)
1. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.
Ooms M; Rietjens R; Rangarajan JR; Vunckx K; Valdeolivas S; Maes F; Himmelreich U; Fernandez-Ruiz J; Bormans G; Van Laere K; Casteels C
Neurobiol Aging; 2014 Dec; 35(12):2858-2869. PubMed ID: 25018107
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease.
Casteels C; Vandeputte C; Rangarajan JR; Dresselaers T; Riess O; Bormans G; Maes F; Himmelreich U; Nguyen H; Van Laere K
Exp Neurol; 2011 Jun; 229(2):440-9. PubMed ID: 21459091
[TBL] [Abstract][Full Text] [Related]
3. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
4. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
Hebb AL; Robertson HA; Denovan-Wright EM
Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.
Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR
Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.
Hebb AL; Robertson HA; Denovan-Wright EM
Eur Neuropsychopharmacol; 2008 May; 18(5):339-63. PubMed ID: 17913473
[TBL] [Abstract][Full Text] [Related]
7. Type 1 cannabinoid receptor mapping with [18F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism.
Casteels C; Martinez E; Bormans G; Camon L; de Vera N; Baekelandt V; Planas AM; Van Laere K
Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2354-63. PubMed ID: 20680268
[TBL] [Abstract][Full Text] [Related]
8. PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression.
Fazio P; Fitzer-Attas CJ; Mrzljak L; Bronzova J; Nag S; Warner JH; Landwehrmeyer B; Al-Tawil N; Halldin C; Forsberg A; Ware J; Dilda V; Wood A; Sampaio C; Varrone A;
Mov Disord; 2020 Apr; 35(4):606-615. PubMed ID: 31967355
[TBL] [Abstract][Full Text] [Related]
9. MR-based spatial normalization improves [18F]MNI-659 PET regional quantification and detectability of disease effect in the Q175 mouse model of Huntington's disease.
Bertoglio D; Verhaeghe J; Kosten L; Thomae D; Van der Linden A; Stroobants S; Wityak J; Dominguez C; Mrzljak L; Staelens S
PLoS One; 2018; 13(10):e0206613. PubMed ID: 30365550
[TBL] [Abstract][Full Text] [Related]
10. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease.
Miller S; Hill Della Puppa G; Reidling J; Marcora E; Thompson LM; Treanor J
J Huntingtons Dis; 2014; 3(4):333-41. PubMed ID: 25575954
[TBL] [Abstract][Full Text] [Related]
11. Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease.
Niccolini F; Foltynie T; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Kapur S; Rabiner EA; Gunn RN; Piccini P; Politis M
Brain; 2015 Oct; 138(Pt 10):3003-15. PubMed ID: 26210536
[TBL] [Abstract][Full Text] [Related]
12. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
Harada A; Suzuki K; Kimura H
J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
[TBL] [Abstract][Full Text] [Related]
13. Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging.
Russell DS; Jennings DL; Barret O; Tamagnan GD; Carroll VM; Caillé F; Alagille D; Morley TJ; Papin C; Seibyl JP; Marek KL
Neurology; 2016 Feb; 86(8):748-54. PubMed ID: 26802091
[TBL] [Abstract][Full Text] [Related]
14. Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D
Fazio P; Schain M; Mrzljak L; Amini N; Nag S; Al-Tawil N; Fitzer-Attas CJ; Bronzova J; Landwehrmeyer B; Sampaio C; Halldin C; Varrone A
Neuroimage; 2017 May; 152():330-339. PubMed ID: 28254508
[TBL] [Abstract][Full Text] [Related]
15. PET imaging shows loss of striatal PDE10A in patients with Huntington disease.
Ahmad R; Bourgeois S; Postnov A; Schmidt ME; Bormans G; Van Laere K; Vandenberghe W
Neurology; 2014 Jan; 82(3):279-81. PubMed ID: 24353339
[TBL] [Abstract][Full Text] [Related]
16. Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers.
Wilson H; Niccolini F; Haider S; Marques TR; Pagano G; Coello C; Natesan S; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
J Neurol Sci; 2016 Sep; 368():243-8. PubMed ID: 27538642
[TBL] [Abstract][Full Text] [Related]
17. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
Laprairie RB; Bagher AM; Rourke JL; Zrein A; Cairns EA; Kelly MEM; Sinal CJ; Kulkarni PM; Thakur GA; Denovan-Wright EM
Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
[TBL] [Abstract][Full Text] [Related]
18. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.
Niccolini F; Haider S; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Piccini P; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
Brain; 2015 Oct; 138(Pt 10):3016-29. PubMed ID: 26198591
[TBL] [Abstract][Full Text] [Related]
19. Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [
de Laat B; Kling YE; Schroyen G; Ooms M; Hooker JM; Bormans G; Van Laere K; Ceccarini J
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):492-502. PubMed ID: 34142214
[TBL] [Abstract][Full Text] [Related]
20. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.
Lastres-Becker I; Berrendero F; Lucas JJ; Martín-Aparicio E; Yamamoto A; Ramos JA; Fernández-Ruiz JJ
Brain Res; 2002 Mar; 929(2):236-42. PubMed ID: 11864629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
